Tardive dyskinesia and substrates of energy metabolism in CSF



	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted



	Email this article to a Colleague
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Add to My Articles & Searches
	Download to citation manager



	Citing Articles via HighWire
	Citing Articles via Google Scholar



	Articles by Goff, D. C.
	Articles by Coyle, J. T.
	Search for Related Content



	PubMed Citation
	Articles by Goff, D. C.
	Articles by Coyle, J. T.

Am J Psychiatry 1995; 152:1730-1736
Copyright © 1995 by American Psychiatric Association

REGULAR ARTICLES

Tardive dyskinesia and substrates of energy metabolism in CSF

DC Goff, G Tsai, MF Beal and JT Coyle
Schizophrenia Research Program, Erich Lindemann Mental Health Center, Boston, MA, USA.

OBJECTIVE: This study was undertaken to assess the relationships among CSF concentrations of substrates of mitochondrial energy metabolism, neuroleptic medication, and neurological side effects. METHOD: CSF was obtained from 25 patients with schizophrenia; seven were unmedicated and 11 had tardive dyskinesia. CSF concentrations of four substrates of mitochondrial energy metabolism (Krebs cycle)--alanine, aspartate, lactate, and pyruvate--were determined. Tardive dyskinesia was measured with the Abnormal Involuntary Movement Scale (AIMS), and parkinsonism was measured with the Simpson-Angus Rating Scale. RESULTS: CSF concentrations of alanine were significantly elevated in the medicated patients when tardive dyskinesia status was controlled for. CSF aspartate concentrations were significantly elevated in patients with tardive dyskinesia when medication status was controlled for and were significantly correlated with total scores on the AIMS. CONCLUSIONS: These results are consistent with a model linking neuroleptic-induced neurological side effects with impairment of mitochondrial energy metabolism, possibly mediated by inhibition of complex 1 of the electron transport chain.

This article has been cited by other articles:

J. A. Lieberman, G. D. Tollefson, C. Charles, R. Zipursky, T. Sharma, R. S. Kahn, R. S. E. Keefe, A. I. Green, R. E. Gur, J. McEvoy, et al.
Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis
Arch Gen Psychiatry, April 1, 2005; 62(4): 361 - 370.
[Abstract] [Full Text] [PDF]

J.-C. Leveque, W. Macias, A. Rajadhyaksha, R. R. Carlson, A. Barczak, S. Kang, X.-M. Li, J. T. Coyle, R. L. Huganir, S. Heckers, et al.
Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs
J. Neurosci., June 1, 2000; 20(11): 4011 - 4020.
[Abstract] [Full Text] [PDF]

D. C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D. A. Schoenfeld, D. L. Hayden, R. McCarley, and J. T. Coyle
A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia
Arch Gen Psychiatry, January 1, 1999; 56(1): 21 - 27.
[Abstract] [Full Text] [PDF]

G. Tsai, D. C. Goff, R. W. Chang, J. Flood, L. Baer, and J. T. Coyle
Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia
Am J Psychiatry, September 1, 1998; 155(9): 1207 - 1213.
[Abstract] [Full Text]

Get information about faster international access.